TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
邵幼雲SHAO, YU-YUN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
83筆
31
Ghassan Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, Joseph O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Bolorsukh Gansukh, Serge Lyashchenko, Jennifer Ma, Peter Wan, Yu-Yun Shao, Zhong-Zhe Lin, Catherine Frenette, Bert O’Neil, Lawrence Schwartz, Peter Smith-Jones, Toshihiko Ohtomo, Takayoshi Tanaka, Hideo Morikawa, Yuko Maki, Norihisa Ohishi, Ya-Chi Chen, Tamara Agajanov, Frederic Boisserie, Laura Di Laurenzio, Ray Lee, Steven Larson, Ann-Lii Cheng, Jorge Carrasquilo. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2017 Feb; 79: 421-429#
32
Yi-Hsin Liang, Chih-Hsin Wei, Wen-Hui Hsu, Yu-Yun Shao, Ya-Chin Lin, Pei-Chun Chou, Ann-Lii Cheng, Kun-Huei Yeh. Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. Support Care Cancer 2017 Feb; 25: 533-539#
33
Hsiao-Hui Lin,Wen-Chi Feng, Li-Chun Lu, Yu-Yun Shao, Chih-Hung Hsu, Ann-Lii Cheng. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Letters 2016 Oct; 381: 58-66#
34
Yu-Yun Shao, Tsung-Hao Liu, Ying-Hui Lee, Chih-Hung Hsu, Ann-Lii Cheng. Modified CLIP with Objective Liver Reserve Assessment Retains Prognosis Prediction for Patients with Advanced Hepatocellular Carcinoma. J Gastroenterol Hepatol 2016 Jul; 31: 1336-1341#
35
Yi-Hsin Liang, Yu-Yun Shao, Bin-Chi Liao, Ho-Sheng Lee, James Chih-Hsin Yang, Ho-Min Chen, Chun-Ju Chiang, Ann-Lii Cheng, Mei-Shu Lai. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. Journal of Cancer 2016 Jul; 7: 1515-1523#
36
Chih-Peng Lin, Chih-Hung Hsu, Wen-Mei Fu, Ho-Min Chen, Ying-Hui Lee, Mei-Shu Lai, Yu-Yun Shao. Key Opioid Prescription Concerns in Cancer Patients: A Nationwide Study. Acta Anaesthesiologica Taiwanica 2016 Jun; 54: 51-56 (corresponding author)
37
Kuo-Hsing Chen, Yu-Yun Shao, Ho-Min Chen, Yu-Lin Lin, Zhong-Zhe Lin, Mei-Shu Lai, Ann-Lii Cheng, Kun-Huei Yeh. Primary tumor site is a useful predictor of cetuximab efficacy in the third-Line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer 2016 May; 16: 327-334#
38
Chiun Hsu, Liang-In Lin, Yu-Che Cheng, Zi-Rui Feng, Yu-Yun Shao, Ann-Lii Cheng, Da-Liang Ou. Cyclin E1 Inhibition Can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clin Cancer Res 2016 May; 22:2555-2564#
39
Yi-Hsin Liang, Yu-Yun Shao, Ho-Min Chen, Chiu-Lin Lai, Zhong-Zhe Lin, Raymond Nien-Chen Kuo, Ann-Lii Cheng, Kun-Huei Yeh, and Mei-Shu Lai. Young patients with colorectal cancer have increased risk of second primary malignancies. Jpn J Clin Oncol 2015 Nov; 45: 1029-1035#
40
Yu-Yun Shao, Chih-Hung Hsu and Ann-Lii Cheng. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 2015 Sep; 21: 10336-10347#
